Literature DB >> 26893707

Continuous prostate-specific antigen rise despite salvage radiotherapy following radical prostatectomy: Pattern of clinical relapse and predictive factors.

Carsten Nieder1, Kirsten Marienhagen2, Roy M Kristensen3, Torbjørn Sørbye3, Lars Hoem3.   

Abstract

Salvage radiotherapy for post-prostatectomy biochemical recurrence does not always control the disease. It would be useful to identify patients who would not benefit from radiotherapy to the prostate bed prior to making treatment recommendations. One such group of patients is those who experience continuously rising prostate-specific antigen (PSA) despite radiotherapy. The purpose of this study was to identify risk factors for continuous PSA increase and the pattern of radiological relapse during follow-up. We performed a retrospective comparison of two patient groups with PSA decline or continuous increase following salvage radiotherapy to the prostate bed. All patients received 3-D conformal radiotherapy (35 fractions of 2 Gy). Patients with continuous PSA increase were more likely to have had complete surgical resection (negative margins) and a shorter interval to radiotherapy (<24 months). However, the only statistically significant risk factor was Gleason score. Sixty-four percent of patients with a Gleason score of 9 developed continuously increasing PSA, indicating that residual subclinical cancer was not located in the prostate bed. The median time to radiological recurrence was 43 months. Isolated pelvic nodal recurrence was uncommon. Almost all patients with radiological recurrence had high-risk disease, in particular stage pT3. In conclusion, the majority of patients with biologically aggressive tumors with Gleason score 9 were not adequately treated with prostate bed radiotherapy alone. The predominant pattern of radiological recurrence was outside of the pelvis. Therefore, the problem of distant micrometastases has to be addressed.

Entities:  

Keywords:  prostate cancer; prostate-specific antigen; radiation oncology; radiotherapy; salvage treatment

Year:  2015        PMID: 26893707      PMCID: PMC4734180          DOI: 10.3892/ol.2015.4005

Source DB:  PubMed          Journal:  Oncol Lett        ISSN: 1792-1074            Impact factor:   2.967


  25 in total

1.  Predicting PSA failure following salvage radiotherapy for a rising PSA post-prostatectomy: from the CaPSURE database.

Authors:  O Kenneth Macdonald; Anthony V D'Amico; Natalia Sadetsky; Dennis C Shrieve; Peter R Carroll
Journal:  Urol Oncol       Date:  2007-12-03       Impact factor: 3.498

2.  Prostate cancer-specific survival following salvage radiotherapy vs observation in men with biochemical recurrence after radical prostatectomy.

Authors:  Bruce J Trock; Misop Han; Stephen J Freedland; Elizabeth B Humphreys; Theodore L DeWeese; Alan W Partin; Patrick C Walsh
Journal:  JAMA       Date:  2008-06-18       Impact factor: 56.272

3.  Salvage radiotherapy in patients with prostate cancer and biochemical relapse after radical prostatectomy : Long-term follow-up of a single-center survey.

Authors:  Gunnar Lohm; Jörg Lütcke; Basil Jamil; Stefan Höcht; Konrad Neumann; Wolfgang Hinkelbein; Thomas Wiegel; Dirk Bottke
Journal:  Strahlenther Onkol       Date:  2014-02-28       Impact factor: 3.621

4.  Efficacy of salvage radiotherapy plus 2-year androgen suppression for postradical prostatectomy patients with PSA relapse.

Authors:  Richard Choo; Cyril Danjoux; Sandra Gardner; Gerard Morton; Ewa Szumacher; D Andrew Loblaw; Patrick Cheung; Maria Pearse
Journal:  Int J Radiat Oncol Biol Phys       Date:  2009-05-04       Impact factor: 7.038

5.  Phase III postoperative adjuvant radiotherapy after radical prostatectomy compared with radical prostatectomy alone in pT3 prostate cancer with postoperative undetectable prostate-specific antigen: ARO 96-02/AUO AP 09/95.

Authors:  Thomas Wiegel; Dirk Bottke; Ursula Steiner; Alessandra Siegmann; Reinhard Golz; Stephan Störkel; Norman Willich; Axel Semjonow; Rainer Souchon; Michael Stöckle; Christian Rübe; Lothar Weissbach; Peter Althaus; Udo Rebmann; Tilman Kälble; Horst Jürgen Feldmann; Manfred Wirth; Axel Hinke; Wolfgang Hinkelbein; Kurt Miller
Journal:  J Clin Oncol       Date:  2009-05-11       Impact factor: 44.544

6.  Predicting the outcome of salvage radiation therapy for recurrent prostate cancer after radical prostatectomy.

Authors:  Andrew J Stephenson; Peter T Scardino; Michael W Kattan; Thomas M Pisansky; Kevin M Slawin; Eric A Klein; Mitchell S Anscher; Jeff M Michalski; Howard M Sandler; Daniel W Lin; Jeffrey D Forman; Michael J Zelefsky; Larry L Kestin; Claus G Roehrborn; Charles N Catton; Theodore L DeWeese; Stanley L Liauw; Richard K Valicenti; Deborah A Kuban; Alan Pollack
Journal:  J Clin Oncol       Date:  2007-05-20       Impact factor: 44.544

7.  Does neoadjuvant hormone therapy improve outcome in prostate cancer patients receiving radiotherapy after radical prostatectomy?

Authors:  Howard Huaihan Pai; Brenna Eldridge; Darcy Bishop; Abraham Alexander; Mary Lesperance; Paul Blood; Jan Lim; Charles Ludgate
Journal:  Can J Urol       Date:  2009-04       Impact factor: 1.344

8.  Salvage intensity-modulated radiotherapy for rising PSA after radical prostatectomy.

Authors:  Gert De Meerleer; Valérie Fonteyne; Sabine Meersschout; Caroline Van den Broecke; Geert Villeirs; Nicolaas Lumen; Piet Ost; Katrien Vandecasteele; Wilfried De Neve
Journal:  Radiother Oncol       Date:  2008-09-02       Impact factor: 6.280

9.  Salvage radiotherapy for rising prostate-specific antigen levels after radical prostatectomy for prostate cancer: dose-response analysis.

Authors:  Johnny Ray Bernard; Steven J Buskirk; Michael G Heckman; Nancy N Diehl; Stephen J Ko; Orlan K Macdonald; Steven E Schild; Thomas M Pisansky
Journal:  Int J Radiat Oncol Biol Phys       Date:  2009-05-21       Impact factor: 7.038

10.  Comprehensive microRNA profiling of prostate cancer cells after ionizing radiation treatment.

Authors:  Chung-Man Leung; Sung-Chou Li; Ting-Wen Chen; Meng-Ru Ho; Ling-Yueh Hu; Wen-Shan Liu; Tony T Wu; Ping-Chi Hsu; Hong-Tai Chang; Kuo-Wang Tsai
Journal:  Oncol Rep       Date:  2014-01-21       Impact factor: 3.906

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.